TELA Bio, Inc. (TELA)
| Market Cap | 34.77M |
| Revenue (ttm) | 80.28M |
| Net Income (ttm) | -38.83M |
| Shares Out | 44.74M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,706 |
| Open | 0.775 |
| Previous Close | 0.800 |
| Day's Range | 0.775 - 0.782 |
| 52-Week Range | 0.501 - 2.200 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+157.37%) |
| Earnings Date | May 12, 2026 |
About TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile... [Read more]
Financial Performance
In 2025, TELA Bio's revenue was $80.28 million, an increase of 15.84% compared to the previous year's $69.30 million. Losses were -$38.83 million, 2.62% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TELA stock is "Strong Buy." The 12-month stock price target is $2.0, which is an increase of 157.37% from the latest price.
News
TELA Bio to Announce First Quarter 2026 Financial Results
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction so...
TELA Bio Analysts Cut Their Forecasts After Q4 Results
TELA Bio, Inc. (NASDAQ: TELA) reported mixed results for the fourth quarter on Tuesday.
TELA Bio Earnings Call Transcript: Q4 2025
Delivered 16% revenue growth in 2025 and record Q4 results amid major commercial restructuring, with strong European performance and new product launches. 2026 guidance is for at least 8% revenue growth, reflecting prudence as a large cohort of new sales reps ramps up.
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction so...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio Transcript: Piper Sandler 37th Annual Healthcare Conference
Poised for mainstream adoption, the company is expanding its product portfolio and sales force, targeting at least 15% revenue growth next year. Financial efficiency is improving, with a strong capital position and new products set to drive further upside.
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...
These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings
TELA Bio Inc (NASDAQ: TELA) reported mixed results for the third quarter on Thursday.
TELA Bio Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 9% year-over-year to $20.7 million, driven by strong adoption and international expansion. Net loss narrowed, salesforce efficiency improved, and guidance calls for at least 16% revenue growth in 2025 and 15% in 2026.
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today annou...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today r...
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Hernia and reconstructive surgery markets are rapidly shifting to natural, non-permanent solutions, with robotic procedures and novel materials driving growth. The company is expanding its commercial team, optimizing sales strategies, and leveraging strong clinical data and unique contracting to accelerate revenue and market access. Financial discipline is expected to support profitability.
TELA Bio Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 26% year-over-year to $20.2 million, with strong gains in OviTex PRS and international markets. Gross margin improved, losses narrowed, and full-year guidance was reiterated, supported by new product launches, expanded clinical data, and a patient-centric sales strategy.
TELA Bio Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today r...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...
TELA Bio to Announce Second Quarter 2025 Financial Results
MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio Transcript: Jefferies Global Healthcare Conference 2025
The company is expanding in hernia and plastic surgery markets with innovative, cost-effective products, gaining share as the industry shifts from traditional biomaterials. Stable gross margins, new leadership, and strong clinical data support growth, with profitability expected as revenue rises.
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
Based on market research, inguinal hernia repair is the most common type of hernia repair Based on market research, inguinal hernia repair is the most common type of hernia repair
TELA Bio Appoints Jeffrey Blizard as President
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...
TELA Bio Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 12% year-over-year to $18.5M, driven by strong OviTex and PRS demand, with European sales up 17%. Gross margin was 67.6%, and 2025 revenue guidance of $85–$88M was reaffirmed, despite a modest tariff headwind.
TELA Bio to Announce First Quarter 2025 Financial Results
MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction so...